Appendix 3 contains a list of abbreviations used in this document. To provide clinicians with a comprehensive set of data, the absolute risk difference and number needed to treat or harm, if they were published and their inclusion was deemed appropriate, are provided in the guideline, along with confi- dence intervals (CIs) and data related to the relative treatment effects, such as odds ratio (OR), relative risk (RR), hazard ratio, or incidence rate ratio. 1.2. Organization of the Writing Committee The writing committee was composed of physicians, cardiovas- cular interventionalists, surgeons, general internists, imagers, nurses, and pharmacists. The writing committee included repre- sentatives from the ACP, AATS, PCNA, SCAI, and STS. 1.3. Document Review and Approval This document was reviewed by 2 external reviewers nomi- nated by both the ACCF and the AHA; 2 reviewers nomi- nated by the ACP, AATS, PCNA, SCAI, and STS; and 19 content reviewers, including members of the ACCF Imaging Council, ACCF Interventional Scientific Council, and the AHA Council on Clinical Cardiology. Reviewers RWI information was collected and distributed to the writing committee and is published in this document (Appendix 2). Because extensive peer review comments resulted in substan- tial revision, the guideline was subjected to a second peer review by all official and organizational reviewers. Lastly, the imaging sections were peer reviewed separately, after an update to that evidence base. This document was approved for publication by the gov- erning bodies of the ACCF, AHA, ACP, AATS, PCNA, SCAI, and STS. 1.4. Scope of the Guideline These guidelines are intended to apply to adult patients with stable known or suspected IHD, including new-onset chest pain (ie, low-risk unstable angina [UA]), or to adult patients with stable pain syndromes (Figure 1). 